VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Apr 9, 2007 -- Inflazyme Pharmaceuticals Ltd. (Toronto:IZP.TO - News) today announced that it has received a statement from Helicon Therapeutics of New York regarding the outcome of the proof of concept Phase 2a study with IPL455,903 (HT-0712) in Age Associated Memory Impairment (AAMI).
